Skip to main content
. Author manuscript; available in PMC: 2013 Feb 17.
Published in final edited form as: ACS Chem Biol. 2011 Nov 11;7(2):331–339. doi: 10.1021/cb200134p

Figure 5. HDAC inhibition titration and selective toxicity against leukemia cells.

Figure 5

a) NQN-1 and analogs display selective inhibition against HDAC6. Minimal inhibitory activity was observed for other HDACs (HDAC1 shown and Supporting Information). b) NQN analogs cause selective toxicity against leukemia cells consistent with their ability to inhibit HDAC6 in vitro. The least potent inhibitor of HDAC6, NQN-3, did not inhibit MV4-11 proliferation (>100 μM). Resting PBMC viability was not affected by either NQN-1 or NSC treatments. PBMC proliferation was inhibited at 3.24 μM which is 4-fold higher than the toxicity against AML cells ex vivo.